Suppression of the TRIF-dependent signaling pathway of TLRs by epoxomicin
- Authors
- Kim, Su Y.; Shin, Seokwon; Kwon, Minji; Youn, Daniel; Sung, Nam J.; Kim, Na H.; Park, Sin-Aye; Youn, Hyung-Sun
- Issue Date
- Sep-2021
- Publisher
- John Wiley & Sons Ltd.
- Keywords
- epoxomicin; IRF3; MyD88; Toll-like receptor; TRIF
- Citation
- Archiv der Pharmazie, v.354, no.9
- Journal Title
- Archiv der Pharmazie
- Volume
- 354
- Number
- 9
- URI
- https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/19319
- DOI
- 10.1002/ardp.202100130
- ISSN
- 0365-6233
1521-4184
- Abstract
- Toll-like receptors (TLRs) can recognize specific signatures of invading microbial pathogens and activate a cascade of downstream signals to induce the secretion of inflammatory cytokines, chemokines, and type I interferons. The activation of TLRs triggers two downstream signaling pathways: the MyD88- and the TRIF-dependent pathways. To evaluate the therapeutic potential of epoxomicin, a member of the linear peptide alpha',beta'-epoxyketone first isolated from an actinomycetes strain, we examined its effects on signal transduction via TLR signaling pathways. Epoxomicin inhibited the activation of NF-kB and IRF3 induced by TLR agonists, decreased the expression of interferon-inducible protein-10, and inhibited the activation of NF-kB and IRF3 induced by overexpression of downstream signaling components of TLR signaling pathways. These results suggest that epoxomicin can regulate both the MyD88- and TRIF-dependent signaling pathways of TLRs. Thus, it might have potential as a new therapeutic drug for a variety of inflammatory diseases.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medical Sciences > Department of Biomedical Laboratory Science > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.